(2R,3S,4R,5S)-6-[[(1S)-1-carboxy-4-oxobutyl]amino]-2,3,4,5-tetrahydroxy-6-oxohexanoic acid

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: (2R,3S,4R,5S)-6-[[(1S)-1-carboxy-4-oxobutyl]amino]-2,3,4,5-tetrahydroxy-6-oxohexanoic acid
• 化学式: C₁₁H₁₇NO₁₀
• 分子量: 323.25
• InChiKey: CTKQALQRFXNTLB-GWVFRZDISA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -3.9
• 重原子数：
  22
• 可旋转键数：
  10
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.64
• 拓扑面积：
  202
• 氢给体数：
  7
• 氢受体数：
  10

文献信息

• FUNCTIONALIZED EXENDIN-4 DERIVATIVES
  申请人：Sanofi

  公开号：EP3400957A1

  公开（公告）日：2018-11-14

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

  本发明涉及 exendin-4 衍生物及其医疗用途，例如用于治疗代谢综合征疾病，包括糖尿病和肥胖症，以及减少过量食物摄入。
• Functionalized Exendin-4 derivatives
  申请人：SANOFI

  公开号：US10253079B2

  公开（公告）日：2019-04-09

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

  本发明涉及 exendin-4 衍生物及其医疗用途，例如用于治疗代谢综合征疾病，包括糖尿病和肥胖症，以及减少过量食物摄入。
• Exendin-4 derivatives as dual GLP1/glucagon agonists
  申请人：SANOFI

  公开号：US10758592B2

  公开（公告）日：2020-09-01

  The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.

  本发明涉及 exendin-4 衍生物及其医疗用途，例如用于治疗代谢综合征疾病，包括糖尿病和肥胖症，以及减少过量食物摄入。
• EXENDIN-4 DERIVATIVES AS DUAL GLP1/GIP OR TRIGONAL GLP1/GIP/GLUCAGON AGONISTS
  申请人：SANOFI

  公开号：EP2934566B1

  公开（公告）日：2017-06-21
• EXENDIN-4 DERIVATIVES AS DUAL GLP1/GLUCAGON AGONISTS
  申请人：SANOFI

  公开号：EP2906595A1

  公开（公告）日：2015-08-19